



Governor Jay Inslee Leads Ribbon Cutting Ceremony at Nohla's Seattle Headquarters

Seattle, Washington -- (February 8 2017) - Nohla Therapeutics Inc. (Nohla), a leading innovator in the development of universal donor cellular therapies for the treatment of patients with blood cancers, announced today that Washington Governor Jay Inslee led a ribbon cutting ceremony Wednesday morning to celebrate the official opening of Nohla's headquarters in Seattle. Governor Inslee met with Nohla's senior leaders including Kathleen Fanning, President and Chief Executive Officer, and Dr. Colleen Delaney, scientific founder and Chief Medical Officer, as well as Steven Gillis, PhD, Chairman of the Board of Directors for Nohla and the Managing Director for ARCH Venture Partners in Seattle. Following a tour of the facility, Governor Inslee gave a speech to attendees during the ribbon cutting ceremony. Also present for and participating in the ceremony was Gregg Gordon, who underwent a cord blood transplant with Nohla's lead product over five years ago as a participant in a clinical trial, and his wife, Caryn.

Nohla was founded in December 2015 to further develop a cellular therapy technology invented at Fred Hutchinson Cancer Research Center. The celebration today marked the official opening of the 6,300 square foot state-of-the-art facility, which will house both laboratory research and administrative staff in the South Lake Union neighborhood of Seattle. This represents a major milestone for the Company as this facility will enable additional process development utilizing its revolutionary product platform, which enables the ex vivo expansion and directed differentiation of cord blood stem/progenitor cells resulting in "off the shelf" universal donor cellular therapies for a number of indications. Nohla is backed by top-tier investors including ARCH Venture Partners, 5AM Ventures, and Jagen.

"The official opening of Nohla's headquarters is an important step in our path to further develop and commercialize our groundbreaking cell therapy so we can make it available to patients undergoing cancer treatment as soon as possible," stated Dr. Colleen Delaney. "We are thrilled with Governor Inslee's participation during today's ribbon cutting ceremony and are excited to establish our headquarters in Washington."

Nohla's one-of-a kind universal donor product (which does not require any HLA matching) has been used safely across multiple clinical studies in over 100 patients at risk of severe infection and other complications after intensive chemotherapy and cord blood transplantation. This product is currently being evaluated in a multicenter, randomized Phase 2b study in the setting of myeloablative cord blood transplant for leukemia and other blood cancers. The Company also plans to conduct a Phase 2 randomized study in the setting of high dose chemotherapy for acute myelogenous leukemia (AML).

"We are proud to have led the opening ceremony of Nohla's headquarters and to welcome this rapidly growing biotech company to the state of Washington. Today's opening is indicative of the State's ongoing commitment to promote key advancements in the scientific and technological fronts," commented Governor Inslee.



About Nohla Therapeutics

Nohla Therapeutics Inc. (Nohla) is a clinical stage company dedicated to the development of universal donor cellular therapies for the treatment of patients with life threatening blood cancers. The Company is leveraging a platform developed over the past two decades at Fred Hutchinson Cancer Research Center which enables the ex vivo expansion and directed differentiation of cord blood stem/progenitor cells resulting in “off-the-shelf” universal donor cellular therapies (which can be used on demand without the need for HLA matching). Nohla is evaluating the ability of these “off-the-shelf” cryopreserved expanded cell products to reduce infection and other complications of neutropenia in several clinical settings including two lead programs involving multi-center, randomized clinical trials: a Phase IIb study in the setting of cord blood transplant and a global Phase II study in the setting of high dose chemotherapy for acute myelogenous leukemia (AML). Nohla is supported by top-tier healthcare dedicated institutional investors including ARCH Venture Partners, 5AM Ventures, and Jagen Group.

For more information, please contact:

Investors

Candice Knoll
Blueprint Life Science Group
+1 415-375-3340 Ext. 4
cknoll@bplifescience.com

Media

Esther Cuno
Director, Corporate Communications
+1 206 519 5313
estherc@nohlatherapeutics.com